Holen Sie sich die Stockscreener-App
13.50
3.61%
0.47
Vorhandelsmarkt:
14.19
0.69
+5.11%
Schlusskurs vom Vortag:
$13.03
Offen:
$13.11
24-Stunden-Volumen:
267.55K
Relative Volume:
0.68
Marktkapitalisierung:
$191.77M
Einnahmen:
$13.11M
Nettoeinkommen (Verlust:
$-124.02M
KGV:
-0.9466
EPS:
-14.261
Netto-Cashflow:
$-107.25M
1W Leistung:
+6.22%
1M Leistung:
-2.88%
6M Leistung:
-25.50%
1J Leistung:
-31.05%
1-Tages-Spanne:
$12.72
$13.55
1-Wochen-Bereich:
$12.00
$14.09
52-Wochen-Spanne:
$11.60
$69.97
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Company Profile
Firmenname
Tonix Pharmaceuticals Holding Corp
Sektor
Branche
Telefon
212-980-9155
Adresse
200 CONNELL DRIVE, SUITE 3100, BERKELEY HEIGHTS, NY
Compare TNXP vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TNXP
Tonix Pharmaceuticals Holding Corp
|
13.50 | 191.77M | 13.11M | -124.02M | -107.25M | -14.26 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-04-18 | Eingeleitet | Noble Capital Markets | Outperform |
| 2019-04-18 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2017-08-18 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2016-09-07 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2016-02-17 | Bestätigt | Oppenheimer | Outperform |
| 2015-11-04 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2015-06-12 | Eingeleitet | Oppenheimer | Outperform |
| 2015-02-17 | Bestätigt | ROTH Capital | Buy |
| 2014-09-29 | Bestätigt | ROTH Capital | Buy |
Alle ansehen
Tonix Pharmaceuticals Holding Corp Aktie (TNXP) Neueste Nachrichten
Tonix stock rises on commercial payer coverage (TNXP:NASDAQ) - Seeking Alpha
Tonix Pharma Expands TONMYA Coverage Across U.S. Payers - TipRanks
Tonix secures GPO coverage for fibromyalgia drug TONMYA - Investing.com
35 million insured Americans gain access to Tonix fibromyalgia drug - Stock Titan
Tonix (NASDAQ: TNXP) secures TONMYA fibromyalgia coverage for 35M insured lives - Stock Titan
Tonix Pharmaceuticals Secures Commercial Payer Coverage for - GlobeNewswire
Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Rating Upgraded by TD Cowen - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
Cash per share of Tonix Pharmaceuticals Holding Corp. – DUS:TPM0 - TradingView
Tonix Pharmaceuticals (TNXP) to Release Quarterly Earnings on Monday - MarketBeat
TD Cowen initiated coverage on Tonix Pharma with a new price target - Quantisnow
TD Cowen initiates Tonix Pharma stock with buy rating, $22 target - Investing.com India
TD Cowen initiates Tonix Pharma stock with buy rating, $22 target By Investing.com - Investing.com Australia
Tonix Pharmaceuticals Holding (TNXP) price target decreased by 15.76% to 55.42 - MSN
Tonix Pharmaceuticals Holding Corp. Files Form 8-K Current Report with NASDAQ Listing Details (May 1, 2026) - Minichart
Tonix Pharmaceuticals (NASDAQ: TNXP) gives early look at Q1 2026 sales - Stock Titan
TNXP Stock Price, Quote & Chart | TONIX PHARMACEUTICALS HOLDIN (NASDAQ:TNXP) - ChartMill
Tonix Pharmaceuticals (TNXP) Proxy filing Summary - Quartr
Tonix Pharmaceuticals (TNXP) Announces Phase 2 Study Plans for L - GuruFocus
Tonix plans Phase 2 Lyme disease prevention study in 2027 - Investing.com UK
Tonix plans Phase 2 Lyme disease prevention study in 2027 By Investing.com - Investing.com Australia
Tonix Pharma Advances TNX-4800 Lyme Disease Prevention Program - TipRanks
Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Plans for an Adaptive Phase 2 Field Study of TNX-4800 (anti-Borrelia OspA monoclonal antibody) for the Prevention of Lyme Disease at the 4th Annual Ticks and Tickborne Diseases Symp - The Manila Times
Tonix (NASDAQ: TNXP) plans Phase 2 Lyme antibody study for 2027 - Stock Titan
A two-dose Lyme prevention antibody is planned for a U.S. field study - Stock Titan
Tonix Pharmaceuticals Announces Presentation of Phase 1 - GlobeNewswire
Tonix Pharmaceuticals stock hits new 52-week low: What's driving the action? - MSN
Tonix Pharmaceuticals Stock Jumps Into Retail Spotlight After $25M Buyback Boost — Traders See ‘Blueprint For Rerating’ - MSN
(TNXP) Risk Channels and Responsive Allocation - Stock Traders Daily
Tonix Pharmaceuticals Holding Corp (STU:TPM0) Stock Price & 30 Year Financial Data - GuruFocus
Wall Street Zen Downgrades Tonix Pharmaceuticals (NASDAQ:TNXP) to Sell - MarketBeat
Tonix Pharmaceuticals Showcases Promising Preclinical Immuno-Oncology Advances with TNX-1700 and TNX-4700 at AACR 2026 1 - Minichart
Tonix Pharma Highlights Preclinical Progress in Oncology Pipeline - TipRanks
Preclinical cancer data for Tonix (NASDAQ: TNXP) TNX-1700 and TNX-4700 - Stock Titan
Tonix Pharmaceuticals Presents Updates on Preclinical Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2026 - Yahoo Finance
Tonix Pharmaceuticals (NASDAQ:TNXP) Upgraded by Wall Street Zen to "Hold" Rating - MarketBeat
(TNXP) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Tonix Pharmaceuticals Announces Publication of Steady-State Pharmacokinetics of TONMYA® After 20 Days of Daily Dosing in the Peer-Reviewed Journal, Clinical Pharmacology in Drug Development - Sahm
Tonix publishes pharmacokinetic study on fibromyalgia drug By Investing.com - Investing.com Australia
Tonix Pharmaceuticals (TNXP) Reports Positive Findings on TNX-10 - GuruFocus
Tonix publishes pharmacokinetic study on fibromyalgia drug - Investing.com
Tonix Pharmaceuticals Announces Publication of Steady-State - GlobeNewswire
Analyst Upgrade: Can Tonix Pharmaceuticals Holding Corp stock outperform in a bear marketWeekly Earnings Recap & Reliable Price Breakout Alerts - baoquankhu1.vn
TNXP Options Volatility — NASDAQ:TNXP - TradingView — Track All Markets
TNXP Options Chain — NASDAQ:TNXP - TradingView
Profit Recap: Will Tonix Pharmaceuticals Holding Corp announce a stock split2026 Analyst Calls & Daily Chart Pattern Signals - baoquankhu1.vn
Will Tonix Pharmaceuticals Holding Corp stock benefit from M AInflation Watch & Daily Stock Trend Watchlist - baoquankhu1.vn
Why Tonix's External Atty Saw GC Role As A 'Natural Choice' - Law360
Finanzdaten der Tonix Pharmaceuticals Holding Corp-Aktie (TNXP)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.14%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):